Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Teresa Donnell

Nurse Practitioner, Family Tulsa, OK Nurse Practitioner

NPI 1902183387 CMS profile 10451864

6160 S Yale Ave, Tulsa, OK 74136

Open in the dashboard

General payments

$9,114

523 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Teresa Donnell of Tulsa, OK is reported in the CMS Open Payments database as having received $9,114 across 523 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $66 3
2023 General $4,064 214
2022 General $3,688 216
2021 General $1,295 90

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Teresa Donnell
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Teresa Donnell were reported at $0. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Teresa Donnell Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,295 $124 $35–$379 $132
2022 $3,688 $141 $44–$430 $149
2023 $4,064 $154 $49–$476 $160
2024 $66 $165 $51–$504 $164
2025 $0 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. AbbVie, Inc. $2,623 188 payments
  2. Amgen Inc. $888 47 payments
  3. Janssen Biotech, Inc. $737 33 payments
  4. AstraZeneca Pharmaceuticals LP $673 35 payments
  5. UCB, Inc. $530 30 payments
  6. GlaxoSmithKline, LLC. $480 27 payments
  7. Lilly USA, LLC $399 15 payments
  8. Horizon Therapeutics plc $347 18 payments
  9. Novartis Pharmaceuticals Corporation $318 19 payments
  10. Mallinckrodt Hospital Products Inc. $304 16 payments
  11. Other $1,815 95 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $9,047 522 payments
  2. Education $67 1 payment
Products named General payments · program years 2021–2024
  1. RINVOQ $2,391 175 payments
  2. SKYRIZI $762 60 payments
  3. SAPHNELO $654 34 payments
  4. SIMPONI ARIA $631 30 payments
  5. Cimzia $530 30 payments
  6. BENLYSTA $480 27 payments
  7. STELARA $475 19 payments
  8. REMICADE $475 19 payments
  9. SIMPONI $475 19 payments
  10. Enbrel $417 19 payments
  11. Other $5,005 273 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

154

Median for Nurse Practitioner: 389

Drug cost

$155,052

Median for Nurse Practitioner: $21,885

Branded share of claims

24%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 15 $147,969
Hydroxychloroquine Sulfate Generic 61 $4,974
Duloxetine Hcl Generic 21 $1,078
Methotrexate Methotrexate Sodium Brand 22 $555
Sulfasalazine Generic 14 $371
Prednisone Generic 21 $104

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$42 — —
Cimzia
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

523 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record